What is PreciThera?
PreciThera operates at the intersection of computational biology and rare disease pathology. By leveraging advanced data-driven methodologies, the company identifies novel biological targets associated with bone dysfunction, aiming to provide precision medicine solutions for patients with limited treatment options. The firm's strategic focus on heterogeneous genetic disorders allows it to address both the primary skeletal symptoms and the broader systemic issues inherent in these conditions. As a player in the high-growth biotech sector, PreciThera distinguishes itself through a rigorous, science-first methodology that bridges the gap between complex genetic data and actionable therapeutic interventions. Its market position is bolstered by a robust intellectual property pipeline and a commitment to addressing significant unmet medical needs in the rare disease landscape.
How much funding has PreciThera raised?
PreciThera has raised a total of $29M across 1 funding round:
Series A
$29M
Series A (2017): $29M with participation from Emerillon Capital, Fonds de solidarité FTQ, Arix Bioscience, CTI Life Sciences, and Sanderling Ventures
Key Investors in PreciThera
CTI Life Sciences
CTI Life Sciences Fund is a prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, emphasizing long-term value creation.
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm specializing in building new biomedical companies through early-stage financing and active management.
Emerillon Capital
Emerillon Capital is an investment firm that provides strategic support and capital to companies within the innovation ecosystem, focusing on growth and development.
What's next for PreciThera?
Following this major enterprise-level funding, PreciThera is expected to prioritize the expansion of its clinical pipeline and the refinement of its computational discovery platform. The strategic allocation of these funds will likely support the transition of lead candidates toward human clinical trials, a critical phase for validating the efficacy of their targeted therapeutic strategies. Furthermore, the company is poised to strengthen its internal research capabilities, potentially seeking additional partnerships to broaden the application of its technology across other genetic disorders. By maintaining a disciplined focus on long-term value creation and scientific rigor, PreciThera aims to solidify its standing as a leader in the development of next-generation treatments for rare genetic conditions, ultimately driving significant improvements in patient outcomes and long-term clinical success.
See full PreciThera company page
